Phase II Trial of Amivantamab Plus Monochemotherapy in Platinum Unfit NSCLC Patients With EGFR exon20 Insertion Mutations.

NCT07392658 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Metastatic NSCLC - Non-Small Cell Lung Cancer

Interventions

DRUG: Amivantamab

Sponsor

Fondazione Ricerca Traslazionale